What's new in blistering disorders?

Current Allergy and Asthma Reports

Volumn 7, Issue 4, 2007, Pages 255-263

  Chaudhari, Paru ^b   Marinkovich, M Peter ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BULLOUS PEMPHIGOID ANTIGEN 1; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DAPSONE; DESMOGLEIN; ERYTHROMYCIN; GOLD; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADJUVANT THERAPY; ANTIGEN BINDING; BLISTER; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYTHEMATOUS PEMPHIGUS; GLUTEN FREE DIET; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; LOW DRUG DOSE; MONOTHERAPY; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PARANEOPLASTIC PEMPHIGUS; PARANEOPLASTIC SYNDROME; PASSIVE IMMUNIZATION; PATHOGENESIS; PEMPHIGOID; PEMPHIGOID GESTATIONIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PREMATURITY; REVIEW; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT; WOUND CARE;

ANIMALS; AUTOIMMUNE DISEASES; BLISTER; DISEASE MODELS, ANIMAL; HUMANS; SKIN DISEASES, VESICULOBULLOUS;

EID: 34250728970     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-007-0038-7     Document Type: Review

References (72)

1. Lin MS, Mascaro JM Jr, Liu Z, et al.: The desmosome and hemidesmosome in cutaneous autoimmunity. Clin Exp Immunol 1997, 107(Suppl 1):9-15.
2. Keene DR, Marinkovich MP, Sakai LY: Immunodissection of the connective tissue matrix in human skin. Microsc Res Tech 1997, 38:394-406.
3. Klatte DH, Kurpakus MA, Grelling KA, Jones JC: Immunochemical characterization of three components of the hemidesmosome and their expression in cultured epithelial cells. J Cell Biol 1989, 109(6 Pt 2):3377-3390.
4. Marinkovich MP: The molecular genetics of basement membrane diseases. Arch Dermatol 1993, 129:1557-1565.
5. Wiche G: Role of plectin in cytoskeleton organization and dynamics. J Cell Sci 1998, 111(Pt 17):2477-2486.
6. Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999, 285:1028-1032.
7. Masunaga T: Epidermal basement membrane: its molecular organization and blisteriag disorders. Connect Tissue Res 2006, 47:55-66.
8. Aumailley M, B. Gayraud, Structure and biological activity of the extracellular matrix. J Mol Med 1998, 76:253-265.
9. Stanley JR: Pemphigus. In Fitzpatrick's Dermatology in General Medicine, edn 6. Edited by Freedberg IM. New York: McGraw-Hill; 1999:654-666.
10. Ishii K, Amagai M, Hall RP, et al.: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbeat assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997, 159:2010-2017.
11. Diaz LA, Arteaga LA, Hilario-Vargas J, et al.: Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem. J Invest Dermatol 2004, 123:1045-1051.
12. Anhalt GJ: Paraneoplastic pemphigus. Adv Dermatol 1997, 12:77-96; discussion 97.
13. Sison-Fonacier L, JC Bystryn: Heterogeneity of pemphigus vulgaris antigens. Arch Dermatol 1987, 123:1507-1510.
14. Hanakawa Y, Matsuyoshi N, Stanley JR: Expression of desmoglein 1 compensates for genetic loss of desmoglein 3 in keratiaocyte adhesion. J Invest Dermatol 2002, 119:27-31.
15. Mahoney MG, Wang Z, Rothenberger K, et al.: Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999, 103:461-468.
16. Kricheli D, David M, Frusic-Zlotkin M, et al.: The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000, 143:337-342.
17. Anhalt GJ, et al.: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982, 306:1189-1196.
18. Aoki-Ota M, Tsunoda K, Ota T, et al.: A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br J Dermatol 2004, 151:346-354.
19. Muller R, Svoboda V, Wenzel E, et al.: IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris. Exp Dermatol 2006, 15:606-614.
20. Lanza A, Cirillo N, Ferniano F, Gombos F: How does acantholysis occur in pemphigus vulgaris: a critical review. J Cutan Pathol 2006, 33:401-412.
21. Bystryn JC, Grando SA: A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis. J Am Acad Dermatol 2006, 54:513-516.
22. Frusic-Zlotkin M, Raichenberg D, Wang X, et al.: Apoptotic mechanism in pemphigus autoimmunoglobulins-induced acantholysis-possible involvement of the EGF receptor. Autoimmunity 2006, 39:563-575.
23. Bystryn JC: Adjuvant therapy of pemphigus. Arch Dermatol 1984, 120:941-951.
24. Ratnam KV, Phay KL, Tan CK: Pemphigus therapy with oral prednisolone regimens: a 5-year study. Int J Dermatol 1990, 29:363-367.
25. Dick SE, Werth VP: Pemphigus: a treatment update. Autoimmunity 2006, 39:591-599.
26. Beissert S, Werfel T, Frieling U, et al.: A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006, 142:1447-1454.
27. Cummins DL, Mimouni D, Anhalt GJ, Nousari CH: Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003, 49:276-280.
28. Guillaume JC, Roujeau JC, Morel P, et al.: Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988, 124:1659-1663.
29. Sondergaard K, Carstens J, Jorgensen J, Zachariae H: The steroid-sparing effect of long-term plasmapheresis in pemphigus. Acta Derm Venereol 1995, 75:150-152.
30. Turner MS, Sutton D, Sauder DN: The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000, 43:1058-1064.
31. Bystryn JC, Jiao D: IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 2006, 39:601-607.
32. El Tal AK, et al.: Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigas vulgaris. J Am Acad Dermatol 2006, 55:449-459.
33. Ahmed AR, Posner MR, Spigelman Z, Ahmed AR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006, 355:1772-1779.
34. Stanley JR: Bullous pemphigoid. In Fitzpatrick's Dermatology in General Medicine, edn 6. Edited by Freedberg IM. New York: McGraw-Hill; 2003:574-580.
35. Al-Fouzan AW, Galadari I, Oumeish I, Oumeish OY: Herpes gestationis (pemphigoid gestationis). Clin Dermatol 2006, 24:109-112.
36. Yancey KB: Cicatricial pemphigoid. In Fitzpatrick's Dermatology in General Medicine, edn 6. Edited by Freedberg IM. New York: McGraw-Hill; 2003:581-586.
37. Egan CA, Lazarova Z, Darling TN, et al.: Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore) 2003, 82:177-186.
38. Liu Z, Diaz LA, Troy JL, et al.: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993, 92:2480-2488.
39. Yamamoto K, Inoue N, Masuda R, et al.: Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid. J Invest Dermatol 2002, 118:485-492.
40. Liu Z, Giudice GJ, Swartz SJ, et al.: The role of complement in experimental bullous pemphigoid. J Clin Invest 1995, 95:1539-1544.
41. Nelson KC, Zhao M, Schroeder PR, et al.: Role of different pathways of the complement cascade in experimental bullous pemphigoid. J Clin Invest 2006, 116:2892-2900.
42. Laffitte E, Skaria M, Jaunin F, et al.: Autoantibodies to the extracellular and intracellular domain of bullous pemphigoid 180, the putative key autoantigen in bullous pemphigoid, belong predominantly to the IgG1 and IgG4 subclasses. Br J Dermatol 2001, 144:760-768.
43. Liu Z: Are anti-BP180 IgG1 or IgG4 autoantibodies pathogenic? J Invest Dermatol 2002, 119:989-990.
44. Liu Z, Shapiro SD, Zhou X, et al.: A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000, 105:113-123.
45. Liu Z, Li N, Diaz LA, et al.: Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005, 115:879-887.
46. Kiss M, Husz S, Janossy T, et al.: Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005, 24:1-10.
47. Gammon WR, Fine JD, Forbes M, Briggaman RA: Immunofluorescence on split skin for the detection and differentiation of basement membrane zone autoantibodies. J Am Acad Dermatol 1992, 27:79-87.
48. Kromminga A, Sitaru C, Hagel C, et al.: Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 2004, 111:146-152.
49. Yoshida M, Hamada T, Amagai M, et al.: Enzyme-linked immonosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006, 41:21-30.
50. Joly P, Roujeau JC, Benichou J, et al.: A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
51. Walsh SR, Hogg D, Mydlarski PR: Bullous pemphigoid: from bench to bedside. Drugs 2005, 65:905-926.
52. Ahmed AR: Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001, 45:679-690.
53. Chu J, Bradley M, Marinkovich MP: Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003, 139:813-815.
54. Mockenhaupt M, Grosber M, Norganer J: Daclizumab: a novel therapeutic option in severe bullous pemphigoid. Acta Derm Venereol 2005, 85:65-66.
55. Guide SV, Marinkovich MP: Linear IgA bullous dermatosis. Clin Dermatol 2001, 19:719-727.
56. Hirako Y, Nishizawa Y, Sitaru C, et al.: The 97-kDa (LABD97) and 120-kDa (LAD-1) fragments of bullous pemphigoid antigen 180/type XVII collagen have different N-termini. J Invest Dermatol 2003, 121:1554-1556.
57. Marinkovich MP, Taylor TB, Keene DR, et al.: LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996, 106:734-738.
58. Ishiko A, Shimizu H, Masunaga T, et al.: 97-kDa linear IgA bullous dermatosis (LAD) antigen localizes to the lamina lucida of the epidermal basement membrane. J Invest Dermatol 1996, 106:739-743.
59. Zillikens D, Herzele K, Georgi M, et al.: Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801. J Invest Dermatol 1999, 113:947-953.
60. Akahoshi Y, Kanda G, Anan S, Yoshida H: Dermo-epidermal blister formation by linear IgA dermatosis sera in normal human skin in organ culture. J Dermatol 1987, 14:352-358.
61. Allen J, Wojnarowska F: Linear IgA disease: the IgA and IgG response to dermal antigens demonstrates a chiefly IgA response to LAD285 and a dermal 180-kDa protein. Br J Dermatol 2003, 149:1055-1058.
62. Nicolas ME, Krause PK, Gibson LE, Murray JA: Dermatitis herpetiformis. Int J Dermatol 2003, 42:588-600.
63. Marietta E, Black K, Camilleri M, et al.: A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest 2004, 114:1090-1097.
64. Woodley DT, Gammon WR, Briggaman RA: Epidermolysis bullosa acquisita. In Fitzpatrick's Dermatology in General Medicine, edn 6. Edited by Freedberg IM. New York: McGraw-Hill; 2003:609-616.
65. Lapiere JC, Woodley DT, Parente MG, et al.: Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 1993, 92:1831-1839.
66. Sitaru C, Mihai S, Otto C, et al.: Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005, 115:870-878.
67. Woodley DT, Chang C, Saadat P, et al.: Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005, 124:958-964.
68. Sitaru C, Chiriac MT, Mihai S, et al.: Induction of complement-fixing antoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 2006, 177:3461-3468.
69. Shimanovich I, Mihai S, Oostingh GJ, et al.: Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004, 204:519-527.
70. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG: Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
71. Rioux JD, Abbas AK: Paths to understanding the genetic basis of autoimmune disease. Nature 2005, 435:584-589.
72. Fathman CG, Soares L, Chan SM, Utz PJ: An array of possibilities for the study of autoimmunity. Nature 2005, 435:605-611.